If You Invested in Harrow Health Inc (HROWM)

HROWM is the ticker symbol for a series of senior notes issued by Harrow, Inc., a company in the pharmaceutical preparations sector. According to an SEC filing, these securities are identified as 11.875% Senior Notes due 2027 and are listed on The Nasdaq Stock Market LLC under the symbol HROWM. While Harrow, Inc. is the operating company, HROWM represents its debt securities rather than common equity.

The available regulatory disclosure indicates that Harrow, Inc. operates in the pharmaceutical preparations sector. Investors researching HROWM are therefore looking at a fixed-income instrument tied to a pharmaceutical-focused issuer. The notes have a stated interest rate and maturity year, which define their basic structure as senior notes.

Harrow, Inc. also has other securities registered, including 8.625% Senior Notes due 2026 listed on Nasdaq under the symbol HROWL, and common stock with a par value per share referenced under the symbol HROW. This context helps investors understand that HROWM exists within a broader capital structure that includes both equity and other debt securities.

Auditor changes and governance context

In an 8-K report, Harrow, Inc. disclosed a change in its independent registered public accounting firm. The company’s audit committee dismissed Crowe LLP as the independent registered public accounting firm and approved the appointment of Deloitte & Touche LLP to audit the company’s consolidated financial statements for a subsequent fiscal year, subject to standard client acceptance procedures and an engagement letter. The filing states that Crowe’s report on the company’s financial statements for a referenced year did not contain an adverse opinion or disclaimer of opinion and was not qualified or modified as to uncertainty, audit scope, or accounting principles.

The same filing notes that, during Crowe’s engagement and the related periods described, there were no disagreements with Crowe on accounting principles, financial statement disclosure, or auditing scope or procedure that would have required reference in Crowe’s reports, and no reportable events within the meaning of Item 304(a)(1)(v) of Regulation S-K. The company also requested, and filed as an exhibit, a letter from Crowe addressed to the SEC regarding the disclosures about the change in auditor.

How this relates to HROWM investors

For investors evaluating HROWM senior notes, the information about Harrow, Inc.’s auditor transition provides insight into the company’s financial reporting oversight. The absence of reported disagreements or reportable events with the prior auditor, as described in the filing, is part of the regulatory record surrounding the issuer of the HROWM notes. The listing of HROWM on The Nasdaq Stock Market LLC indicates that these notes are exchange-traded debt securities associated with Harrow, Inc. in the pharmaceutical preparations sector.